3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
12
Terminated
3
Withdrawn
2
Unknown
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Lymphoma
2
Immunoglobulin Light-chain Amyloidosis
2
Triple Negative Breast Neoplasms
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Neoplasms
1
Neoplasm, Residual
1
Malignant Plasma Cell Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Plasma Cell
1
Leukemia
1
Hematologic Diseases
1
Esophageal Stenosis
1
Esophageal Neoplasms
1
Corneal Diseases
1
Breast Cancer Patients Treated With T-DXd
1
Brain Neoplasms
1
Blood Protein Disorders
1
Ann Arbor Stage II Mantle Cell Lymphoma
1
Amyloidosis
1
Interventions
belantamab mafodotin
1
Dexamethasone
1
Cyclophosphamide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Amyloidosis
×
Dexamethasone
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled